Document is current
Any future updates will be listed below
-
Authors
Heesch, Amelie
Florea, Alexandru
Maurer, Jochen
Habib, Pardes
Werth, Laura S.
Hansen, Thomas
Stickeler, Elmar
Sahnoun, Sabri E. M.
Mottaghy, Felix M.
Morgenroth, Agnieszka
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113780, 70113780, 70113779, 70113779)
Deutsche Forschungsgemeinschaft (331065168)
Universitätsklinikum RWTH Aachen
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 13 February 2024
First Online: 20 February 2024
Declarations
:
: FMM is medical advisor for Nanomab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH. He has recently received institutional grants from Nanomab Technology Ltd., Siemens and GE Precision Healthcare LLC. Furthermore he has an interventional research contract with CURIUM.
: All animal experiments were approved by a German competent authority (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen) for compliance with the Animal Protection Act, in conjunction with the regulation for the protection of animals used for experimental and other scientific purposes.
